4Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol, 1999, 31: 929-938.
5Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology, 2002, 35:409-413.
6Lohse AW, zum Biischenfelde KH, Franz B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology, 1999, 29: 1078- 1084.
8Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis, 2002, 22: 365-378.
9Durazzo M, Premoli A, Fagoonee S, et al. Overlap syndromes of autoimmune hepatitis: what is known so far. Dig Dis Sci, 2003, 48: 423-430.
10Conforti A, Leone R, Ghiotto E, et al. Spontaneous reporting of drug related hepatic reactions from two Italy regions (Lombardy and Veneto). Digest Liver Dis, 2000,32 : 716-723.
3European Association for the Study of the Liver.EASL clinical practice guidelines: management of cholestatic liver diseases[J].J Hepatol, 2009,51 : 237-267.
5Han XF, Wang QX, Liu Y. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis, 2012,13: 219-224.
7Michael Brown J, Ball JG, Wright MS.Novel protective mechanisms for S-adenosyl-L-methionine against acetaminophen hepatotoxicity: improvement of key antioxidant enzymatic fimction[J].Toxicol Lett, 2012,212: 320-328.
8Andringa KK, King AL, Eccleston HB, et al.Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine treatments: novel molecular targets of disease and hepatoprotection[J]. Am J Physiol Gastrointest Liver Physiol, 20 ! 0,298 ( 5 ) : G732-745.
9Vincenzi B, Santini D, Frezza AM.The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients aft~cted by resected colorectal cancer treated with adjuvant FOLFOX regimen[J].Expert Opin Drug Saf, 2011,10: 345-349.
10European Association for the Study of the Liver. EASL Clinical Prac- tice Guidelines: management of cholestatic liver diseases [ J]. JHepa- tol,2009,51 (2) :237-267.
